Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving
Ukyo Kondo1, Taku Kikuchi1, Shotaro Sugita1
1Department of Hematology Japanese Red Cross Medical Center Shibuya Tokyo Japan.
Background:
The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear.
Methods:
We retrospectively analyzed RRMM patients treated with elranatamab to assess cumulative incidence and risk factors for CMV reactivation.
Results:
Among 32 patients, the 6-month cumulative incidence of CMV reactivation was 37.3%. High CMV immunoglobulin G (IgG) titers were significantly associated with CMV reactivation (57.9% vs. 9.1%, p = 0.012), while prophylactic immunoglobulin reduced CMV reactivation risk within high CMV IgG group.
Conclusion:
Baseline CMV IgG titers may help guide risk-adapted monitoring and prevention strategies during elranatamab therapy.
